+

PE20060355A1 - TIENO[3,2-b]PIRIDIN-6-CARBONITRILOS COMO INHIBIDORES DE LA QUINASA PROTEICA - Google Patents

TIENO[3,2-b]PIRIDIN-6-CARBONITRILOS COMO INHIBIDORES DE LA QUINASA PROTEICA

Info

Publication number
PE20060355A1
PE20060355A1 PE2005000531A PE2005000531A PE20060355A1 PE 20060355 A1 PE20060355 A1 PE 20060355A1 PE 2005000531 A PE2005000531 A PE 2005000531A PE 2005000531 A PE2005000531 A PE 2005000531A PE 20060355 A1 PE20060355 A1 PE 20060355A1
Authority
PE
Peru
Prior art keywords
pyridin
alkyl
inhibitors
carbonitrile
dichloro
Prior art date
Application number
PE2005000531A
Other languages
English (en)
Inventor
Diane Harris Boschelli
Nan Zhang
Haris Durutlic
Biqi Wu
Sosa Ana Carolina Barrios
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35149207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060355(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20060355A1 publication Critical patent/PE20060355A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE PIRIDINA DE FORMULA II, DONDE W ES NH, NR4, O, ENTRE OTROS; m ES 0, 1 O 2; n ES 1, 2, 3, 4 O 5; q ES 0, 1, 2, 3, 4 O 5; R1 ES FENILO OPCIONALMENTE SUSTITUIDO CON UNO O MAS SUSTITUYENTES J, NO2, CN, ENTRE OTROS; R2 ES R3, J, C(O)XR3 O CHO, ENTRE OTROS; R3 ES ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R4 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION Y A UN PROCEDIMIENTO DE PREPARACION. SON COMPUESTOS PREFERIDOS: 3-BROMO-7-[(2,4-DICLORO-5-METOXIFENIL)AMINO]TIENO[3,2-b]PIRIDIN-6-CARBONITRILO, 7-[(2,4-DICLORO-5-METOXIFENIL)AMINO]-3-(4-FORMILFENIL)TIENO[3,2-b]PIRIDIN-6-CARBONITRILO, 7-[(2,4-DICLORO-5-METOXIFENIL)AMINO]-3-{4-[(DIMETILAMINO)METIL]FENIL}TIENO[3,2-b]PIRIDIN-6-CARBONITRILO, ENTRE OTROS. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA QUINASA Y SON UTILES PARA EL TRATAMIENTO DEL CANCER, ATAQUE APOPLETICO, DOLOR NEUROPATICO, ENTRE OTROS
PE2005000531A 2004-05-14 2005-05-12 TIENO[3,2-b]PIRIDIN-6-CARBONITRILOS COMO INHIBIDORES DE LA QUINASA PROTEICA PE20060355A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/845,710 US7276519B2 (en) 2002-11-25 2004-05-14 Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
PE20060355A1 true PE20060355A1 (es) 2006-05-11

Family

ID=35149207

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000531A PE20060355A1 (es) 2004-05-14 2005-05-12 TIENO[3,2-b]PIRIDIN-6-CARBONITRILOS COMO INHIBIDORES DE LA QUINASA PROTEICA

Country Status (20)

Country Link
US (2) US7276519B2 (es)
EP (1) EP1756117A2 (es)
JP (1) JP2007537262A (es)
KR (1) KR20070015575A (es)
CN (1) CN1950379A (es)
AR (1) AR050248A1 (es)
AU (1) AU2005245820A1 (es)
BR (1) BRPI0511089A (es)
CA (1) CA2564530A1 (es)
CR (1) CR8787A (es)
EC (1) ECSP067087A (es)
GT (1) GT200500109A (es)
MX (1) MXPA06012900A (es)
NO (1) NO20065489L (es)
PA (1) PA8633201A1 (es)
PE (1) PE20060355A1 (es)
RU (1) RU2006137476A (es)
TW (1) TW200602348A (es)
WO (1) WO2005113560A2 (es)
ZA (1) ZA200609422B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831218A2 (en) * 2004-12-23 2007-09-12 F.Hoffmann-La Roche Ag Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
WO2006066913A2 (en) 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors
PE20070619A1 (es) * 2005-09-27 2007-07-02 Wyeth Corp TIENO(2,3-b)PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINAS QUINASA
CA2634158A1 (en) * 2005-12-20 2007-06-28 Gilead Colorado, Inc. Use of 4, 7-dihydrothieno ¬2, 3-b| pyridine compounds in the treatment of cardiovascular diseases
EP2032538A2 (en) * 2006-06-08 2009-03-11 Array Biopharma, Inc. Quinoline compounds and methods of use
TW200900408A (en) * 2007-03-02 2009-01-01 Kyowa Hakko Kogyo Kk Fused pyridine derivative
WO2009041591A1 (ja) * 2007-09-28 2009-04-02 Kyowa Hakko Kirin Co., Ltd. 縮環ピリジン誘導体
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
WO2010036629A2 (en) * 2008-09-26 2010-04-01 National Health Research Institutes Fused multicyclic compounds as protein kinase inhibitors
TW201204733A (en) 2010-06-25 2012-02-01 Kowa Co Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
WO2013117285A1 (en) * 2012-02-09 2013-08-15 Merck Patent Gmbh Furo [3, 2 - b] - and thieno [3, 2 - b] pyridine derivatives as tbk1 and ikk inhibitors
WO2014004376A2 (en) 2012-06-26 2014-01-03 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126970A3 (en) 1983-04-27 1985-11-06 Beecham Group Plc Anxiolytic and anti-depressant thienopyridine derivatives
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
AU9454198A (en) * 1997-11-11 1999-05-31 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
PT2253620E (pt) * 1998-09-29 2014-04-15 Wyeth Holdings Llc 3-cianoquinolinas substituídas como inibidores de proteínas tirosinas quinases
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
PL350920A1 (en) 1999-04-21 2003-02-10 American Cyanamid Co Substituted 3-cyano-[1.7], [1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases
EP1242382B1 (en) 1999-12-29 2007-02-07 Wyeth Tricyclic protein kinase inhibitors
AR035851A1 (es) 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
ES2223827T3 (es) 2000-06-06 2005-03-01 Pfizer Products Inc. Derivados de tiofeno utiles como agentes anticancerigenos.
US20020004511A1 (en) * 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
EP1337513A1 (en) * 2000-11-02 2003-08-27 AstraZeneca AB 4-substituted quinolines as antitumor agents
EP1418917A1 (en) 2001-08-10 2004-05-19 Novartis AG Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
JP5148499B2 (ja) * 2005-05-20 2013-02-20 メチルジーン インコーポレイテッド Ｖｅｇｆ受容体およびｈｇｆ受容体シグナル伝達の阻害剤
PE20070619A1 (es) * 2005-09-27 2007-07-02 Wyeth Corp TIENO(2,3-b)PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINAS QUINASA

Also Published As

Publication number Publication date
ECSP067087A (es) 2007-01-26
NO20065489L (no) 2006-11-28
GT200500109A (es) 2005-12-23
TW200602348A (en) 2006-01-16
CA2564530A1 (en) 2005-12-01
RU2006137476A (ru) 2008-06-20
KR20070015575A (ko) 2007-02-05
PA8633201A1 (es) 2006-05-16
CR8787A (es) 2007-10-02
MXPA06012900A (es) 2007-01-26
BRPI0511089A (pt) 2007-12-26
AU2005245820A1 (en) 2005-12-01
ZA200609422B (en) 2008-07-30
US20040242883A1 (en) 2004-12-02
US20080070913A1 (en) 2008-03-20
JP2007537262A (ja) 2007-12-20
US7276519B2 (en) 2007-10-02
WO2005113560A3 (en) 2006-01-12
CN1950379A (zh) 2007-04-18
AR050248A1 (es) 2006-10-11
EP1756117A2 (en) 2007-02-28
WO2005113560A2 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
ECSP066886A (es) Compuestos y métodos para el tratamiento de dislipidemia
ATE433981T1 (de) Heterocyclische verbindungen
PE20071061A1 (es) Derivados de carbonilo como inhibidores de peptidil-deformilasa (pdf)
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
DE60039508D1 (de) Methoden zur behandlung der essstörungen
PE20061305A1 (es) Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas
ECSP045253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
PE20060355A1 (es) TIENO[3,2-b]PIRIDIN-6-CARBONITRILOS COMO INHIBIDORES DE LA QUINASA PROTEICA
EA200700099A1 (ru) Производные пиридина
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
DK1625126T3 (da) Imidazo- og thiazolopyridiner som JAK3-kinaseinhibitorer
PE20060842A1 (es) Amino-imidazolonas para la inhibicion de b-secretasa
EA200801128A1 (ru) Пери-конденсированные трициклические соединения, полезные в качестве антибактериальных средств
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
ATE484508T1 (de) Furylverbindungen
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
DE60333746D1 (de) Thienylverbindungen
SE0403171D0 (sv) New compounds
EA200400086A1 (ru) Новые производные оксазолидинонов в качестве антибактериальных агентов
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
EA200701734A1 (ru) Новые изотиазолохинолоны и родственные им соединения как антиинфекционные средства
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
PA8587501A1 (es) Benzoxazinonas sustituidas y usos de las mismas

Legal Events

Date Code Title Description
FC Refusal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载